Rheumatology: Take Back Life Miniseries (Part 2): In this episode, we explore the exciting advancements in the treatment of spondyloarthritis, particularly focusing on IL-17 inhibitors, which have significantly transformed the landscape of axial spondyloarthritis care.

These inhibitors are proving highly effective in alleviating disease symptoms, enhancing physical function, and improving patients’ quality of life. We discuss global practises in the prescribing of IL-17 inhibitors, current ASAS and EULAR guidelines, the impact of elevated versus normal CRP on therapy responses, and the importance of shared decision-making in treatment planning.

Join Professor Selmi as he shares his clinical insights and experience using IL-17 inhibitors in managing axial spondyloarthritis, a complex condition where each patient’s journey is unique.

Rheumatology: Take Back Life Miniseries (Part 1): In recent years, significant advancements have been made in therapeutic approaches for psoriatic arthritis (PsA). This discussion delves into the role of interleukin-17 inhibitors in the pathogenesis of PsA, as well as the personalised management of PsA, integrating insights from current international guidelines with emerging real-world evidence.

By bridging the gap between research and practice, this conversation highlights how these advancements are being translated into clinical care, offering tailored treatment approaches that address the diverse needs and challenges faced by PsA patients in everyday settings.